ABCA1 p.Glu1246Gln
[switch to full view]Comments [show]
None has been submitted yet.
PMID: 15218032
[PubMed]
Roosbeek S et al: "Phosphorylation by protein kinase CK2 modulates the activity of the ATP binding cassette A1 transporter."
No.
Sentence
Comment
133
In both systems we engineered several mutants designed at preventing phosphorylation by mutation either of the target threonines and serine, T1242A, T1243A, T1242A/ T1243A, S1255A, or of the downstream cluster of acidic residues, E1245Q, E1246Q, E1245Q/E1246Q.
X
ABCA1 p.Glu1246Gln 15218032:133:238
status: NEWX
ABCA1 p.Glu1246Gln 15218032:133:253
status: NEW159 Compared with WT ABCA1, set as 100%, the PE and PS content in the outer leaflet of the plasma membrane increased up to 130 Ϯ 14 and 123 Ϯ 8% for the T1242A mutant, 154 Ϯ 15 and 148 Ϯ 11% for the T1243A mutant, 170 Ϯ 15 and 207 Ϯ 16% for the T1242A/T1243A mutant, 141 Ϯ 11 and 136 Ϯ 10% for the S1255A mutant, and 141 Ϯ 13 and 120 Ϯ 9% for the E1245Q/E1246Q mutant, respectively (Fig. 4).
X
ABCA1 p.Glu1246Gln 15218032:159:410
status: NEW176 TABLE I Mass spectrometric analysis of NBD1ϩR1 phosphorylation NBD1ϩR1 Tryptic peptide Molecular mass Molecular mass after beta-elimination Phosphorylated residues Da Da WT Leu-1229-Arg-1269 4542.5 4249.5 Thr-1242, Thr-1243, Ser-1255 T1242A Leu-1229-Lys-1250 2483.6 2385.9 Thr-1243 T1242A Val-1251-Arg-1272 2411.6 2313.7 Ser-1255 T1243A Leu-1229-Lys-1250 2483.1 2385.2 Thr-1242 T1243A Val-1251-Arg-1272 2411.2 2313.2 Ser-1255 T1242A/T1243A Leu-1229-Lys-1250 2356.1 2356.1 T1242A/T1243A Val-1251-Arg-1272 2411.6 2313.7 Ser-1255 S1255A Val-1251-Arg-1272 2297.7 2297.7 compared with WT ABCA1.
X
ABCA1 p.Glu1246Gln 15218032:176:12
status: NEW178 The E1245Q/ E1246Q mutation of the downstream acidic residues, which also impairs CK2 activity, similarly increased cellular apoAI and apoAII binding.
X
ABCA1 p.Glu1246Gln 15218032:178:12
status: NEW188 The T1242A and T1243A mutations either alone or in combination and the E1245Q/ E1246Q mutation, which all decrease CK2 activity, increased phospholipid and cholesterol efflux (Fig. 7, A and B).
X
ABCA1 p.Glu1246Gln 15218032:188:79
status: NEW131 In both systems we engineered several mutants designed at preventing phosphorylation by mutation either of the target threonines and serine, T1242A, T1243A, T1242A/ T1243A, S1255A, or of the downstream cluster of acidic residues, E1245Q, E1246Q, E1245Q/E1246Q.
X
ABCA1 p.Glu1246Gln 15218032:131:238
status: NEWX
ABCA1 p.Glu1246Gln 15218032:131:253
status: NEW157 Compared with WT ABCA1, set as 100%, the PE and PS content in the outer leaflet of the plasma membrane increased up to 130 afe; 14 and 123 afe; 8% for the T1242A mutant, 154 afe; 15 and 148 afe; 11% for the T1243A mutant, 170 afe; 15 and 207 afe; 16% for the T1242A/T1243A mutant, 141 afe; 11 and 136 afe; 10% for the S1255A mutant, and 141 afe; 13 and 120 afe; 9% for the E1245Q/E1246Q mutant, respectively (Fig. 4).
X
ABCA1 p.Glu1246Gln 15218032:157:410
status: NEW186 The T1242A and T1243A mutations either alone or in combination and the E1245Q/ E1246Q mutation, which all decrease CK2 activity, increased phospholipid and cholesterol efflux (Fig. 7, A and B).
X
ABCA1 p.Glu1246Gln 15218032:186:79
status: NEW